Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
Recruiting · NCT05652920 · Registry updated 2024-04-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 1 / Phase 2 | 2024-04-03 | NCT05652920 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| OriCell Therapeutics Co., Ltd. | 5 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hunan Cancer Hospital | Changsha | China | 87 |
| Lishui Central Hospital | Lishui | China | 13 |
| Peking University Cancer Hospital | Beijing | China | 11 |
| Sir Run Run Shaw Hospital | Hangzhou | China | 7 |
| The First Hospital of Jilin University | Changchun | China | 46 |
| West China Hospital | Chengdu | China | 21 |
| ZhongShan Hospital Fudan University | Shanghai | China | 22 |